業 績 一 覧 2022

原著

1. Maekawa M, Taniguchi T, Nishio K, Sakai K, Matsushita K, Nakatani K, Ishige T, Ikejiri M, Nishihara H, Sunami K, Yatabe Y, Hatanaka KC, Hatanaka Y, Yamamoto Y, Fukuyama K, Oda S, Saito K, Yokomura M, Kubo Y, Sato H, Tanaka Y, Fuchioka M, Yamasaki T, Matsuda K, Kurachi K, Funai K, Baba S, Iwaizumi M. Precision cancer genome testing needs proficiency testing involving all stakeholders Sci Rep. 2022 Jan; 27;12(1):1494.
2. Baba Y, Kosaka T, Kobayashi H, Nakamura K, Mikami S, Nishihara H, Nakanishi M, Oya M. Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation. BMC medical genomics 2022 Feb; 19;15(1):32.
3. Uemura A, Bandoh N, Goto T, Sato R, Suzuki S, Kubota A, Yamaguchi T, Baba S, Kato Y, Nishihara H, Harabuchi Y, Takei H. Sclerosing Polycystic Adenosis Arising in the Parotid Gland Without PI3K Pathway Mutations. Head Neck Pathol. 2022 Mar;16(1):282-287.
4. Pareira ES, Shibuya M, Ohara K, Nakagawa Y, Kanazawa T, Kamamoto D, Kato Y, Arai E, Aimono E, Yoshida K, Nishihara H, Kanai Y, Sasaki H. The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas. Brain Tumor Pathol. 2022 Apr;39(2):79-87.
5. Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, Kufukihara R, Shojo K, Mikami S, Shinojima T, Kakimi K, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M.  Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. Journal for immunotherapy of cancer 2022 Mar;10(3):e003883.
6. Oba J, Taniguchi H, Sato M, Takanashi M, Yokemura M, Sato Y, Nishihara H. SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan. PloS one 2022 May; 12;17(5):e0263700.
7. Suzuki S, Bandoh N, Goto T, Kubota A, Uemura A, Kono M, Sato R, Takeda R, Sakaue S, Yamaguchi-Isochi T, Nishihara H, Takei H, Harabuchi Y. A retrospective study of parotid gland tumors at a single institution. Oncol Lett. 2022 May; 13;24(1):207.
8. Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D. TP53 variants in p53 signatures and the clonality of STICs in RRSO samples. J Gynecol Oncol. 2022 Jul;33(4):e50.
9. Kamisawa K, Kosaka T, Nakamura K, Yasumizu Y, Hongo H, Takeda T, Matsumoto K, Nishihara H, Oya M. Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations. Cancer Sci. 2022 Sep;113(9):3161-3168.
10. Kufukihara R, Tanaka N, Takamatsu K, Niwa N, Fukumoto K, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Aimono E, Nishihara H, Mizuno R, Oya M. Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma. British journal of cancer 2022 Jun; 28.
11. Song J, Kobayashi Y, Asano Y, Sato A, Taniguchi H, Ui-Tei K. Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo. Cancers (Basel). 2022 Jun; 28;14(13):3162.
12. Ogiri M, Seishima R, Nakamura K, Aimono E, Matsui S, Shigeta K, Chiyoda T, Tanishima S, Okabayashi K, Nishihara H, Kitagawa Y. Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice. Future Oncol. 2022 Jul; 12.
13. Yamada T, Nakanishi Y, Hayashi H, Tanishima S, Mori R, Fujii K, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Matsui A, Tanaka K, Watanabe Y, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi, Hirano S. Targeted Amplicon Sequencing for Primary Tumors and Matched Lymph Node Metastases in Patients with Extrahepatic Cholangiocarcinoma. HPB (Oxford). 2022 Jul;24(7):1035-1043.
14. Mizutani K, Hirade K, Sugiyama S, Kato Y, Nishihara H, Ishihara S. Genomic landscape of treatment-naïve urological cancers using next-generation sequencing-based panel test in the Japanese population. Int J Urol. 2022 Aug;29(8):909-911.
15. Nagai S, Nishihara H, Suzuki T, Nishio K, Taniguchi H, Tsuchihara K, Nakamura K, Takamatsu R, Ueno T, Aburatani H, Kohno T, Kohsaka S. Recommendations related to the analytical equivalence assessment of gene panel testing. Cancer Sci. 2022 Oct;113(10):3282-3290.
16. Aomori T, Sakurai H, Nishihara H. Cancer genomic medicine in Japan and the roles of pharmacists. Pharmacogenet Genomics. 2022 Aug; 1;32(6):242-245.
17. Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagimoto S, et al. DOCK2 is involved in the host genetics and biology of severe COVID-19  Nature. 2022 Sep;609(7928):754-760. 
18. Taniguchi H, Suzuki Y, Imai K, Adachi Y. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies. Cancer Sci. 2022 Sep;113(9):2952-2961.
19. Kobayashi S, Suzuki M, Ueno M, Maruki Y, Okano N, Todaka A, Ozaka M, Tsuji K, Shioji K, Doi K, Kojima Y, Tsumura H, Tanaka K, Higuchi H, Kawabe K, Imaoka H, Yamashita T, Miwa H, Nagano H, Arima S, Hayashi H, Naganuma A, Yamaguchi H, Hisano T, Umemoto K, Ishii S, Nakashima K, Suzuki R, Kitano Y, Misumi T, Furuse J, Ishii H. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer Oncologist. 2022 Oct; 1;27(10):e774-e782.
20. Hoshino S, Matsuda S, Kawakubo H, Yamaguchi S, Nakamura K, Aimono E, Matsui K, Irino T, Fukuda K, Nakamura R, Okita H, Nishihara H, Takeuchi H, Kitagawa Y. Elevation of the Prognostic Factor Plasma Fibrinogen Reflects the Immunosuppressive Tumor Microenvironment in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2022 Oct;29(11):6894-6904.
21. Mizutani K, Yokoi S, Sawada S, Sakamoto I, Kameyama K, Kamei S, Hirade K, Sugiyama S, Matsunaga K, Yamada T, Kato Y, Nishihara H, Ishihara S, Deguchi T. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential VHL Mutations Underlie Multifocal ccRCC Cancer Genomics Proteomics. 2022 Nov-Dec;19(6):740-746.
22. Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Saigusa Y, Yoshino T. Chronological improvement in precision oncology implementation in Japan. Cancer Sci. 2022 Nov;113(11):3995-4000.
23. Imai M, Nakamura Y, Sunami K, Kage H, Komine K, Koyama T, Amano T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Bando H, Makiyama A, Suzuki T, Hirata M, Kohsaka S, Tsuchihara K, Naito Y, Yoshino T. Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors. Cancer Sci. 2022 Nov;113(11):3646-3656.
24. Inoue H, Aimono E, Kasuga A, Tanaka H, Iwasaki A, Saya H, Arima Y. Pixel-Level Clustering of Hematoxylin-Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer. Biomedicines. 2022 Dec; 5;10(12):3133.
25. Imai K, Taniguchi H. Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14. Proc Jpn Acad Ser B Phys Biol Sci. 2022;98(7):325-335.
26. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. JAMA Netw Open. 2022 Dec; 1;5(12):e2245081.

症例報告

1. Hongo H, Kosaka T, Hayashi H, Nakamura K, Nishihara H, Mikami S, Himisha Beltran, Oya M Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian journal of andrology 2022 Jan-Feb;24(1):116-118.
2. Hongo H, Kosaka T, Nakamura K, Mikami S, Nishihara H, Oya M The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation Asian J Urol. 2022 Oct;9(4):480-482.
3. Masuda T, Kosaka T, Nakamura K, Hongo H, Yuge K, Nishihara H, Oya M. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review. BMC medical genomics 2022 May; 21;15(1):118.
4. Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M. A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report. BMC medical genomics 2022 Jun; 20;15(1):138.
5. Kaneko Y, Kosaka T, Nakamura K, Mikami S, Nishihara H, Oya M. Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient IJU Case Rep. 2022 Jun; 24;5(5):323-326.
6. Iwasawa T, Kosaka T, Yasumizu Y, Hongo H, Yanai Y, Baba Y, Matsumoto K, Nakamura K, Nishihara H, Oya M. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series Int J Clin Oncol. 2022 Dec;27(12):1867-1873.
7. Kaneko Y, Kosaka T, Nakamura K, Mikami S, Nishihara H, Oya M. Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient IJU Case Rep. 2022 Jun; 24;5(5):323-326.